nature research

Corresponding author(s):	Ilya Finkelstein
Last updated by author(s):	August 20, 2021

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

_				
CH	-	+1	ct	ics

For all statistical a	analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.				
n/a Confirmed					
The exac	ct sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement				
A staten	nent on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly				
I X I I I	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.				
A descri	ption of all covariates tested				
A descri	ption of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons				
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)				
	hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted lues as exact values whenever suitable.				
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings					
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes					
Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated					
'	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.				
Software a	nd code				
Policy information	n about <u>availability of computer code</u>				
Data collection	N/A				
Data analysis	N/A				
	ng custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and y encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.				

Data

Policy information about <u>availability of data</u>

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The data presented in these figures were generated as part of ref. 36. Raw files associated with figure 3 are available from the corresponding author upon request.

Field-spe	cific re	porting			
Please select the on	e below that is	s the best fit for your research. If you are not sure, read the appropriate sections before making your selection.			
\(\sum_{\text{life sciences}}\)	В	ehavioural & social sciences Ecological, evolutionary & environmental sciences			
For a reference copy of th	ne document with a	all sections, see nature.com/documents/nr-reporting-summary-flat.pdf			
Life scien	ices stu	udy design			
All studies must disc	close on these	points even when the disclosure is negative.			
Sample size	N/A				
Data exclusions	N/A				
Replication	N/A				
Randomization	N/A	V/A			
Blinding	N/A				
We require informatic system or method lists Materials & exp. n/a Involved in the Antibodies Eukaryotic of Animals and Human rese	perimental so perimental so pe	n/a Involved in the study ChIP-seq Flow cytometry Ogy MRI-based neuroimaging			
Antibodies					
Antibodies used	CR302	CR3022 (Abcam, ab273073), anti-human IgG Fab HRP (Sigma-Aldrich, A0293)			
Validation		Abcam notes CR3022 is an anti-spike S1 antibody suitable for ELISAs. Sigma-Aldrich notes anti-human IgG Fab HRP is suitable for ELISAs.			
Eukaryotic ce	ell lines				
Policy information a	about <u>cell lines</u>				
Cell line source(s)		FreeStyle 293-F (Gibco, R79007) and ExpiCHO-S (Gibco, A29127)			
Authentication		Cell lines were purchased commercially and were not further validated.			
Mycoplasma cont	amination	ion FreeStyle 293-F (Gibco, R79007) and ExpiCHO-S (Gibco, A29127) have tested negative for mycoplasma contamination.			

Commonly misidentified lines (See <u>ICLAC</u> register)

N/A